Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.

Trial Details

NCT ID
NCT05210374
Phase
PHASE1
Sponsor
Case Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Disulfiram
  • Copper Gluconate
  • Liposomal Doxorubicin (Doxil)
Locations (sample)
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Must have histologically confirmed relapsed or refractory sarcoma.
  • Must have measurable disease by RECIST criteria at study enrollment
  • Performance status of Karnofsky/Lansky ≥50%
  • Must have normal organ and marrow function as defined below:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →